Peptide Schedule
Cerluten6 residuesAEDPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Cerluten Dosage Calculator
Cerluten is a natural polypeptide bioregulator complex classified as Cytomax A-5 in Khavinson's peptide bioregulator system.
10mcg · Daily
Summary: Add 0mL BAC water to your 10mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Cerluten Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~1-3 hours (estimated; no formal PK studies published)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Cerluten Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | 2x Daily |
| Aggressive | 40mg | 2x Daily |
Note: Cerluten (Cytomax A-5) is a natural polypeptide bioregulator complex extracted from the cerebral cortex of young calves, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It contains low-molecular-weight peptides up to 10,000 Da, including amino acids such as glutamic acid, aspartic acid, alanine, leucine, valine, isoleucine, proline, and serine. Each capsule contains 10 mg of active peptide complex. As an oral capsule, it doesn't require reconstitution. Standard protocols involve 10-30 day courses taken 2-3 times per year. The related synthetic tetrapeptide Cortagen (Ala-Glu-Asp-Pro) was derived from amino acid analysis of this same cerebral cortex source material.
About Cerluten
Cerluten is a natural polypeptide bioregulator complex classified as Cytomax A-5 in Khavinson's peptide bioregulator system. It's produced by extracting low-molecular-weight peptides (up to 10,000 Da) from the cerebral cortex of young calves using a patented isolation and fractionation process developed at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike single-sequence synthetic peptides such as Cortagen or Pinealon, Cerluten contains a mixture of brain-derived peptides that are proposed to act on neural tissue through tissue-specific gene regulation. The primary clinical evidence comes from an open-label study conducted in 2003-2004 at the St. Petersburg Institute, involving 48 patients with CNS conditions including traumatic brain injury sequelae, post-stroke states, and vascular encephalopathy. The study reported positive clinical outcomes in 64.6% of treated patients, with improvements in memory, cognitive function, headache intensity, emotional balance, and sleep quality. However, the study lacked blinding, randomization, and independent replication. It's important to recognize that Cerluten's evidence base has significant limitations. All published clinical data comes from a single institution — the same one that developed the product. There are no controlled human trials in international peer-reviewed journals, no formal pharmacokinetic studies, and no independent safety evaluations. The peptide complex is classified as a dietary supplement in Russia, not a registered pharmaceutical. Researchers interested in brain-derived peptide bioregulators should note that the synthetic derivative Cortagen and the related polypeptide extract Cortexin have somewhat more published data in the international literature.